Philogen S.P.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Antigen associated with rheumatoid arthritis (US 10,385,121) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Novel Antigen Associated with the Neovasculature of Tumour Metastases (US 9,181,347) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for TNF-alpha immunoconjugate therapy for the treatment of brain tumors (US 11,872,288) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,263,041 | Novel Antigen Associated with the Neovasculature of Tumour Metastases In force · High confidence | In force | High confidence | |
| US 10,202,442 | Antigen Associated with Lung Cancers and Lymphomas In force · High confidence | In force | High confidence | |
| US 9,181,347 | Novel Antigen Associated with the Neovasculature of Tumour Metastases In force · High confidence | In force | High confidence | |
| US 8,222,377 | Antigen associated with rheumatoid arthritis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,385,121 | Antigen associated with rheumatoid arthritis In force · From the USPTO record | In force | From the USPTO record | |
| US 9,556,257 | Antigen associated with rheumatoid arthritis In force · From the USPTO record | In force | From the USPTO record | |
| US 9,695,232 | Anti-Ed-A Immunoconjugates for Inflammatory Bowel Disease In force · High confidence | In force | High confidence | |
| US 10,239,939 | Anti-ED-A immunoconjugates for inflammatory bowel disease In force · From the USPTO record | In force | From the USPTO record | |
| US 10,195,253 | Immunocytokine combination therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 9,580,485 | IL-12 immunoconjugate In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 19: 26 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 5 abandoned · 18 no status recorded